The characteristics of side-effects of bromperidol in schizophrenic patients

Psychiatry and Clinical Neurosciences

Volumn 56, Issue 1, 2002, Pages 103-106

  Yasui Furukori, Norio ^a   Kondo, Tsuyoshi ^a   Ishida, Masayuki ^a   Tanaka, Osamu ^a   Mihara, Kazuo ^a   Kaneko, Sunao ^a   Otani, Koichi ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Bromperidol; Extrapyramidal symptoms; Plasma drug concentrations; Side effects

Indexed keywords

BROMPERIDOL;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANTIPSYCHOTIC AGENTS; DYSTONIA; FEMALE; HALOPERIDOL; HUMANS; HYPOKINESIA; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREMOR;

EID: 0036165932     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2002.00936.x     Document Type: Article

References (17)

1. Double-blind study with two butyrophnone derivatives: Bromperidol versus haloperidol
2. Double-blind evaluation of bromperidol versus haloperidol treatment in chronic patients
3. Effects and side-effects bromperidol in comparison with other antipsychotic drugs
4. Clinical evaluation of bromperidol versus halopeidol in psychiatric patients
5. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes
6. The UKU side effect rating scale
7. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography
8. Psychopathology of schizophrenia: Initial validation of a 5-factor model
9. No relationship between -141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: A preliminary study
10. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotic hitherto used
11. Acute dystonia during fixed-dose neuroleptic treatment
12. Predictors of acute dystonia in associated first-episode psychotic patients
13. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist
14. Plasma levels of haloperidol and clinical response
15. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trial
16. Depression in classic versus akinetic-rigid Parkinson's disease